Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

BACKGROUND: Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood–brain barrier continue to be significan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Med
Main Authors: Khan, Muhammad Babar, Ruggieri, Rosamaria, Jamil, Eesha, Tran, Nhan L., Gonzalez, Camila, Mugridge, Nancy, Gao, Steven, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Sarkaria, Jann N., Boockvar, John, Symons, Marc
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2021
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993499/
https://ncbi.nlm.nih.gov/pubmed/33765907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-021-00293-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares